Pre-Conference Focus Day
Tuesday, September 20 | 2022
10:20 am Chair’s Opening Remarks
Novel Formats of Multi-Specifics
10:30 am A Productive Relationship for NK Cell Engagement: Multispecific Two-In-One Antibodies
Synopsis
- Establishing a generic strategy for the generation of trispecific common light chain antibodies
- Applying the technology which is based on chicken immunization, antibody discovery and humanization to the isolation of two-in-one antibodies, where the VL domain targets EGFR and the VH domain PD-L1
- Displaying high tumor selectivity in combination with generating CD16 NK cell engagement potent antibodies
11:00 am Evaluating Novel formats & Testing Efficacy in Fully Immunosufficient in vivo Models
Synopsis
- Presenting findings, using a mouse model of multiple myeloma and anti-BCMA/ CD3 bispecific antibody
- Predicting the risk of immunotoxic events like CRS in vivo models
- Addressing mechanisms of acquired resistance to T cell engager therapy
11:30 am Anticalin Proteins as Key Components in Advanced Multispecific Formats
Synopsis
- Serving robust and highly precise building blocks for target binding in therapeutic bi- and multispecific formats
- Precision targeting and receptor engagement in immuno-oncology can be realized by IgG-Anticalin fusion proteins tailored to the biologic situation
- Monospecific Anticalin and bispecific Duocalin proteins for inhibition of TNF superfamily receptors in therapy of autoimmune diseases can be endowed with half-life extending modules binding to serum proteins
Immune Cell Modulators with Multi-Specifics
Chaired by: Nimish Gera, Vice President – Biologics Research, Mythic Therapeutics
10:30 am ISB 1442: A First-in-Class CD38 & CD47 Bispecific Antibody Innate Cell Modulator for the Treatment of CD38+ Hematological Malignancies
Synopsis
- Understanding and defining the ISB 1442 as a fully human biparatopic bispecific antibody (BsAb) using BEAT® (Bispecific Engagement by Antibodies based on the T-cell receptor) platform to target CD38 and CD47 as treatment for CD38+ malignancies, including multiple myeloma (MM).
- Representing a novel approach for the treatment of CD38+ tumors by co-targeting CD38 and CD47 in a 2+1 biparatopic bispecific antibody
- Showing higher potency in vitro relative to daratumumab in CD38 high/low tumor models as measured
11:00 am Rationale Design of the Next Generation Bifunctional Checkpoint Inhibitors
Synopsis
- Improve therapeutic window of dual-targeting immune checkpoint inhibitors
- Delving into a novel platform to develop bifunctional antibody product
11:30 am IGM-2323 – High Avidity IgM-Based CD20xCD3 Bispecific Antibody for Enhanced T Cell Dependent Killing with Minimal Cytokine Release
Synopsis
- Outlining current state of bispecific antibodies that are largely based on IgGlike scaffolds
- Providing provide high avidity binding to CD20, an scFv fused to the N-terminus of J-chain to provide monovalent engagement of CD3 on T-cells and HSA fused to the C-terminus of J-chain to improve pharmacokinetics
- Demonstrating preclinical IGM-2323 data is highly effective at complement-dependent cytotoxicity and T-cell dependent cellular cytotoxicity killing of tumor cells with minimal cytokine release
12:00 pm
Lunch & Networking
1:00 pm Understanding the Pre-Existing Reactivity of BsAbs for Mitigation Strategies
Synopsis
- Introducing pre-existing serum activity
- Providing and analyzing BsAbs case examples
- Uncovering mitigation strategies
1:30 pm Multimerization of Single-Domain Antibodies Targeting Viral Glycoproteins for Enhanced Potency
Synopsis
- Identification of cross-reactive single-domain antibodies
- Engineering of single-domain antibodies targeting different epitopes into multivalent format for enhanced potency
2:00 pm Roundtable Discussion – Understanding Different Formats Behavior to Identify Which One Works Best
Synopsis
- Harnessing NK Cell in Cancer Therapies by Antibody-Based NK Cell Engager Therapeutics
- Clarifying how formats behave specifically in the system, NK/ Gamma-Delta/ Macrophages/ Immuno-cytokines
- Evolving opportunities within different targets and mechanisms of action to learn which is the best method
- Discussing a case study on blockers, agonist or antagonist
1:00 pm LAG3-Targeted IL15/IL15Rα-Fc (LAG3 x IL15) Fusion Protein for Preferential TIL Expansion
Synopsis
- Engineering LAG3 x IL15 bispecific Fc fusions for optimal activity to LAG3+ TIL with minimal peripheral activity
- Demonstrating potent activity and high selectivity for LAG3+ cell populations in multiple in vitro and in vivo models
- Showing a promising profile of selective delivery to LAG3+ cells and may preferentially expand LAG3+ TIL in patients with cancer, while potentially avoiding systemic toxicity due to off-target activation and expansion of peripheral lymphocytes
2:00 pm Roundtable Discussion – Evaluating Tumor Toxicity for Immune Cell Re-Targeting
Synopsis
- Tackling the on tumor off toxicity cytokine release for immune cell re-targeting
- Reviewing advancements in the field and learning its true potential for success
1:30 pm Developing Switchable Bispecific T Cell Engagers to Fight Cancer
Synopsis
– Innovating a new approach to enable safer and more efficacious T-cell engager therapies through reduced side effects and higher dosing
– Selectively switching on T-LITE’s bispecific functionality through administration of an orally available small-molecule activator
– Enabling the switchable activity of on/off control over the timing and magnitude of T-cell redirection and cytotoxic activity